Moreover, the concurrent alteration of the FRA1 targets, AXL, CDK6, and FSCN1 correlated with worse prognosis in lung adenocarcinoma, low grade glioma, and clear cell renal cell carcinoma (Supplementary Fig. S5A). This evidence concerns the gene FOSL1 and lung adenocarcinoma.